What question did this study set out to answer?

This trial aims to evaluate the safety and efficacy of adding pembrolizumab to palbociclib and endocrine therapy in HR+/HER2- metastatic breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS1-10-19: Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- metastatic breast cancer: Updated results from a phase I/II trial

View Full Paper

Ask AI

Bookmark

This trial aims to evaluate the safety and efficacy of adding pembrolizumab to palbociclib and endocrine therapy in HR+/HER2- metastatic breast cancer.
Conducted as a single-center, open-label, phase I/II trial
Enrolled patients with HR+/HER2- metastatic breast cancer
Administered concurrent or sequential pembrolizumab with palbociclib and endocrine therapy
Primary endpoint: overall response rate; secondary endpoints: progression free survival, overall survival, adverse events.
Enrolled 47 patients with a median age of 55 years
Overall response rate was 62.8% with a median follow-up of 42.6 months
Median progression free survival was 27.1 months
Median overall survival in the first-line setting was 56.8 months
High incidence of grade 2 or higher treatment-related adverse events observed.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical trial investigates treatment efficacy of palbociclib, pembrolizumab, and endocrine therapy in metastatic breast cancer, suggesting promising outcomes.

Cite This Study

LeVee et al. (2026) studied this question.

synapsesocial.com/papers/6996a8efecb39a600b3f040f https://doi.org/10.1158/1557-3265.sabcs25-ps1-10-19

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial investigates treatment efficacy of palbociclib, pembrolizumab, and endocrine therapy in metastatic breast cancer, suggesting promising outcomes.

Abstract PS1-10-19: Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- metastatic breast cancer: Updated results from a phase I/II trial

Key Points

Discussion

Implication

Cite This Study

Abstract PS1-10-19: Palbociclib, pembrolizumab, and endocrine therapy in HR+/HER2- metastatic breast cancer: Updated results from a phase I/II trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider